Fundamentals Data provided by Morningstar.Data provided by Morningstar.
52 Week Range
Avg. Volume (1 month)
as at 24 Feb 3:44pm
No posts found.
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
|Date||Announcement||Price Sensitive?||Time||No. of Pages||File Size|
Jayex Technology Ltd operates in the healthcare industry. It is engaged in the development and provision of healthcare industry service technologies and the development of integrated dispensing automation systems for the pharmaceutical andhealthcare sectors. The company provides the healthcare industry with systems that make managing appointments and communicate patient information effectively. Geographically, It operates in two segments namely, Australia and the United Kingdom of which maximum revenue is generated from the United Kingdom.
|07 Dec 2023||$0.01||$0.00||0.00%||205,000||$0.01||$0.01||$0.01|
|06 Dec 2023||$0.01||$0.00||0.00%||139,500||$0.01||$0.01||$0.01|
|04 Dec 2023||$0.01||$0.00||0.00%||141,723||$0.01||$0.01||$0.01|
|29 Nov 2023||$0.01||$0.00||0.00%||523,434||$0.01||$0.01||$0.01|
|27 Nov 2023||$0.01||$0.00||0.00%||100||$0.01||$0.01||$0.01|
|23 Nov 2023||$0.01||$0.00||0.00%||399,940||$0.01||$0.01||$0.01|
|22 Nov 2023||$0.01||$0.00||0.00%||60||$0.01||$0.01||$0.01|
|20 Nov 2023||$0.01||$0.00||0.00%||100||$0.01||$0.01||$0.01|
|16 Nov 2023||$0.01||$0.00||0.00%||260||$0.01||$0.01||$0.01|
|04 Apr 2023||Michael Boyd||Buy||3,000,000||$31,266||
|17 Mar 2023||Michael Boyd||Issued||250,000,000||$3,750,000||
Conversion of securities.
|17 Mar 2023||Michael Boyd||Exercise||2,700,000||$3,750,000||
Conversion of convertible notes. As per announcement on 13-04-2023
|Mr Michael Denis Boyd||Executive ChairmanExecutive Director||May 2017||
Mr Boyd is the Chairman of the Company and has been involved since its inception in 2014. Based in Melbourne, he has led the corporate structuring of the Company and the development of the strategic vision of Groups. On a practical level he has initiated contacts with all stakeholder groups including professional bodies, regulatory boards, wholesale distributors and pharmacy groups and individuals. Mr Boyd has been involved in the creation of new enterprises, both in the private and public sectors, for over 27 years. Mr. Boyd has been successful in developing and growing new projects in diverse areas including healthcare, telecommunications and finance.
|Mr Brian Renwick||Non-Executive Director||Jul 2009||
Mr Renwick is experienced across the pharmaceutical and healthcare sector in Australia. His involvement with sector commenced in finance roles that led into commercial analysis, marketing and sales. From this broad commercial experience in the manufacturing end of the supply chain he moved into the wholesaling with various business development roles in retail and hospital pharmacy. Mr Renwick's roles broadened into commercial and business development including as general manager for a corporate pharmacy business. He has completed two Business Development roles within the CSL Limited group.
|Mr Nicholas Harper||Executive Director||Sep 2020||
Mr Harper has over thirty years of experience working in software development. During that time, he has worked in the public sector (local government), investment banking and the aviation sector in a wide variety of roles and with varied responsibilities. He has worked on implementing and maintaining many different types of software systems from batch valuation systems to real-time data processing. Based in the UK, He also has extensive experience of project management and software team building.
|Ms Melanie Jaye Leydin||Company Secretary||Aug 2015||
|Mr Robert Hadley||Chief Executive Officer||Oct 2022||
|Robert Hadley||Chief Executive Officer||
|Melanie Jaye Leydin||Company Secretary||
|COVENANT HOLDINGS(WA)PTY LTD <BOYD#4 A/C>||103,883,880||36.93%|
|VECTOR LONDON LTD||19,003,378||6.76%|
|MARY KATHLEEN SIMCOX||17,500,000||6.22%|
|TURBINE CAPITAL LIMITED||8,800,000||3.13%|
|DONOVAN PRODUCTS PTY LTD <THE DONOVAN PRODUCTS FAM A/C>||5,025,000||1.79%|
|BODIE INVESTMENTS PTY LTD||5,000,000||1.78%|
|DONOVAN PRODUCTS PTY LTD <FAMILY ACCOUNT>||4,754,693||1.69%|
|MR DEAN HENRY CLEARY <THE CLEARWAY INVESTMENT A/C>||4,140,000||1.47%|
|COVENANT HOLDINGS (WA) PTY LTD <THE BOYD NO 3 A/C>||4,000,000||1.42%|
|MR JOEL DAVID WEBB||3,754,311||1.33%|
|MR JEREMY RUBEN & MRS VANESSA RUBEN <JVR SUPER FUND A/C>||3,008,067||1.07%|
|RHYD-Y-FELIN PTY LTD||3,000,000||1.07%|
|MRS VANESSA FAYE CONNOR||2,970,819||1.06%|
|Citicorp Nominees Pty Limited||2,856,663||1.02%|
|MR DAVID ARITI||2,839,777||1.01%|
|MS PHAROTH SAN & MR KADEN SAN <PKSAN SUPERFUND A/C>||2,835,172||1.01%|
|AMG CORPORATE PTY LTD <THE AMG SUPER FUND A/C>||2,549,000||0.91%|
|MR JIANJUN ZHOU||2,225,000||0.79%|
|MS CHUNYAN NIU||2,000,000||0.71%|
|MR YULIANG FAN||2,000,000||0.71%|
|INTERNATIONAL BUSINESS NETWORK (SERVICES) PTY LTD||2,000,000||0.71%|
|SUPER MSJ PTY LTD <MSJ SUPER FUND A/C>||2,000,000||0.71%|
|MR CHRISTOPHER JOHN KETTLE||1,913,368||0.68%|